Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News

Table of Contents

Editorials

  • Editorials
    p53 Prognostication: Paradigm or Paradox?
    Jack A. Roth
    Clin Cancer Res November 1 1999 5 (11) 3345-;

  • Editorials
    Drug Resistance: Still on the Learning Curve
    Susan E. Bates
    Clin Cancer Res November 1 1999 5 (11) 3346-3348;

  • Editorials
    Intrathecal Depot Cytarabine Therapy: A Welcome Addition to a Limited Armamentarium
    W. Archie Bleyer
    Clin Cancer Res November 1 1999 5 (11) 3349-3351;

Advances in Brief

  • Advances in Brief
    Rapid Activation of MDR1 Gene Expression in Human Metastatic Sarcoma after in Vivo Exposure to Doxorubicin
    Amir Abolhoda, Amy E. Wilson, Howard Ross, Peter V. Danenberg, Michael Burt and Kathleen W. Scotto
    Clin Cancer Res November 1 1999 5 (11) 3352-3356;

  • Advances in Brief
    Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A ) in Patients with Cancer,
    Alan R. Yuen, Joanne Halsey, George A. Fisher, Jon T. Holmlund, Richard S. Geary, T. Jesse Kwoh, Andrew Dorr and Branimir I. Sikic
    Clin Cancer Res November 1 1999 5 (11) 3357-3363;

  • Advances in Brief
    Vascular Endothelial Growth Factor Levels and Induction of Permeability in Malignant Pleural Effusions
    Brian K. Zebrowski, Seiji Yano, Wenbiao Liu, Raymond M. Shaheen, Daniel J. Hicklin, Joe B. Putnam Jr. and Lee M. Ellis
    Clin Cancer Res November 1 1999 5 (11) 3364-3368;

Clinical Trials

  • Clinical Trials
    A Phase I and Pharmacological Study of Protracted Infusions of Crisnatol Mesylate in Patients with Solid Malignancies
    Miguel A. Villalona-Calero, Thierry Petit, John Kuhn, Patrick Cobb, Maura Kraynak, S. Gail Eckhardt, Ronald Drengler, Cecelia Simmons, Pedro Santabarbara, Daniel D. Von Hoff and Eric K. Rowinsky
    Clin Cancer Res November 1 1999 5 (11) 3369-3378;

  • Clinical Trials
    Coadministration of Oral Cyclosporin A Enables Oral Therapy with Paclitaxel
    Jetske M. Meerum Terwogt, Mirte M. Malingré, Jos H. Beijnen, Wim W. ten Bokkel Huinink, Hilde Rosing, Franciska J. Koopman, Olaf van Tellingen, Martha Swart and Jan H. M. Schellens
    Clin Cancer Res November 1 1999 5 (11) 3379-3384;

  • Clinical Trials
    Phase I and Imaging Trial of a Monoclonal Antibody Directed against Gastrin-releasing Peptide in Patients with Lung Cancer
    Arvind Chaudhry, Jorge A. Carrasquillo, Ingalill L. Avis, Noriyuki Shuke, James C. Reynolds, Richard Bartholomew, Steven M. Larson, Frank Cuttitta, Bruce E. Johnson and James L. Mulshine
    Clin Cancer Res November 1 1999 5 (11) 3385-3393;

  • Clinical Trials
    A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients with Neoplastic Meningitis from Solid Tumors
    Michael J. Glantz, Kurt A. Jaeckle, Marc C. Chamberlain, Surasak Phuphanich, Lawrence Recht, Lode J. Swinnen, Bernard Maria, Susan LaFollette, G. Berry Schumann, Bernard F. Cole and Stephen B. Howell
    Clin Cancer Res November 1 1999 5 (11) 3394-3402;

  • Clinical Trials
    Classification and Regression Tree Analysis of 1000 Consecutive Patients with Unknown Primary Carcinoma
    Kenneth R. Hess, Marie C. Abbruzzese, Renato Lenzi, Martin N. Raber and James L. Abbruzzese
    Clin Cancer Res November 1 1999 5 (11) 3403-3410;

  • Clinical Trials
    A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa, and Paclitaxel followed by Mitoxantrone, Thiotepa, and Paclitaxel with Autologous Hematopoietic Cell Support for Metastatic Breast Cancer
    Wendy W. Hu, Gwynn D. Long, Keith E. Stockerl-Goldstein, Laura J. Johnston, Nelson J. Chao, Robert S. Negrin and Karl G. Blume
    Clin Cancer Res November 1 1999 5 (11) 3411-3418;

  • Clinical Trials
    A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer
    Karen Kelly, Zhaoxing Pan, Marie E. Wood, James Murphy and Paul A. Bunn Jr.
    Clin Cancer Res November 1 1999 5 (11) 3419-3424;

  • Clinical Trials
    A Predictive Model for Relapse in High-Risk Primary Breast Cancer Patients Treated with High-Dose Chemotherapy and Autologous Stem-Cell Transplant
    Yago Nieto, Pablo J. Cagnoni, Elizabeth J. Shpall, Xuesheng Xu, James Murphy, James Vredenburgh, Nelson J. Chao, Scott I. Bearman and Roy B. Jones
    Clin Cancer Res November 1 1999 5 (11) 3425-3431;

  • Clinical Trials
    AIDS-related Kaposi’s Sarcoma: A Phase II Study of Liposomal Doxorubicin
    Tony W. Cheung, Scot C. Remick, Nozar Azarnia, Jo Ann Proper, Jose R. Barrueco and Bruce J. Dezube
    Clin Cancer Res November 1 1999 5 (11) 3432-3437;

  • Clinical Trials
    α-Difluoromethylornithine as Treatment for Metastatic Breast Cancer Patients
    Joyce A. O’Shaughnessy, Laurence M. Demers, Stephen E. Jones, James Arseneau, Pankaj Khandelwal, Timothy George, Robert Gersh, David Mauger and Andrea Manni
    Clin Cancer Res November 1 1999 5 (11) 3438-3444;

Molecular Oncology, Markers, Clinical Correlates

  • Molecular Oncology, Markers, Clinical Correlates
    Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype
    Zhenfeng Duan, Aynn J. Feller, Richard T. Penson, Bruce. A. Chabner and Michael V. Seiden
    Clin Cancer Res November 1 1999 5 (11) 3445-3453;

  • Molecular Oncology, Markers, Clinical Correlates
    Prospective Assessment of Allelic Losses at 4p14–16 in Colorectal Cancer: Two Mutational Patterns and a Locus Associated with Poorer Survival
    Rosa Arribas, Maria Ribas, Rosa-Ana Risques, Laia Masramon, Silvia Tórtola, Eugenio Marcuello, Gemma Aiza, Rosa Miró, Gabriel Capellà and Miguel A. Peinado
    Clin Cancer Res November 1 1999 5 (11) 3454-3459;

  • Molecular Oncology, Markers, Clinical Correlates
    Expression of Nuclear Receptor Interacting Proteins TIF-1, SUG-1, Receptor Interacting Protein 140, and Corepressor SMRT in Tamoxifen-resistant Breast Cancer
    Christina M. W. Chan, Anne E. Lykkesfeldt, Malcolm G. Parker and Mitchell Dowsett
    Clin Cancer Res November 1 1999 5 (11) 3460-3467;

  • Molecular Oncology, Markers, Clinical Correlates
    Aberrant Fragile Histidine Triad Gene Transcripts in Primary Hepatocellular Carcinoma and Liver Cirrhosis
    Laura Gramantieri, Pasquale Chieco, Maddalena Di Tomaso, Livia Masi, Fabio Piscaglia, Stefano Brillanti, Stefano Gaiani, Marco Valgimigli, Alighieri Mazziotti and Luigi Bolondi
    Clin Cancer Res November 1 1999 5 (11) 3468-3475;

  • Molecular Oncology, Markers, Clinical Correlates
    Allelic Loss in Esophageal Squamous Cell Carcinoma Patients with and without Family History of Upper Gastrointestinal Tract Cancer
    Nan Hu, Mark J. Roth, Michael R. Emmert-Buck, Ze-Zhong Tang, Mihael Polymeropolous, Quan-Hong Wang, Alisa M. Goldstein, Xiao-You Han, Sanford M. Dawsey, Ti Ding, Carol Giffen and Philip R. Taylor
    Clin Cancer Res November 1 1999 5 (11) 3476-3482;

  • Molecular Oncology, Markers, Clinical Correlates
    Immunohistochemical Expression of Somatostatin Type 2A Receptor in Neuroendocrine Tumors
    Noriko Kimura, Monika Pilichowska, Fumiko Date, Itaru Kimura and Marcus Schindler
    Clin Cancer Res November 1 1999 5 (11) 3483-3487;

  • Molecular Oncology, Markers, Clinical Correlates
    Human Ovarian Cancer, Cell Lines, and Primary Ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and Are Responsive to MIS
    Peter T. Masiakos, David T. MacLaughlin, Shyamala Maheswaran, Jose Teixeira, Arlan F. Fuller Jr., Paresh C. Shah, David J. Kehas, Mary K. Kenneally, David M. Dombkowski, Thanh U. Ha, Frederic I. Preffer and Patricia K. Donahoe
    Clin Cancer Res November 1 1999 5 (11) 3488-3499;

  • Molecular Oncology, Markers, Clinical Correlates
    TP53 Accumulation Predicts Improved Survival in Patients Resistant to Systemic Cisplatin-based Chemotherapy forMuscle-invasive Bladder Cancer
    K. N. Qureshi, T. R. L. Griffiths, M. C. Robinson, C. Marsh, J. T. Roberts, R. R. Hall, J. Lunec and D. E. Neal
    Clin Cancer Res November 1 1999 5 (11) 3500-3507;

  • Molecular Oncology, Markers, Clinical Correlates
    Apoptosis and Expression of Apoptosis Regulating Proteins bcl-2, mcl-1, bcl-X, and bax in Malignant Mesothelioma
    Ylermi Soini, Vuokko Kinnula, Riitta Kaarteenaho-Wiik, Esko Kurttila, Kaija Linnainmaa and Paavo Pääkkö
    Clin Cancer Res November 1 1999 5 (11) 3508-3515;

  • Molecular Oncology, Markers, Clinical Correlates
    Different Patterns of Angiogenesis in Sarcomas and Carcinomas
    James Tomlinson, Sanford H. Barsky, Scott Nelson, Samuel Singer, Behnaz Pezeshki, Maggie C. Lee, Frederick Eilber and Mai Nguyen
    Clin Cancer Res November 1 1999 5 (11) 3516-3522;

  • Molecular Oncology, Markers, Clinical Correlates
    Characterization of p53 Mutations in Colorectal Liver Metastases and Correlation with Clinical Parameters
    Appolonia Tullo, Anna M. D’Erchia, Kazuo Honda, Ragai R. Mitry, Michael D. Kelly, Nagy A. Habib, Cecilia Saccone and Elisabetta Sbisà
    Clin Cancer Res November 1 1999 5 (11) 3523-3528;

  • Molecular Oncology, Markers, Clinical Correlates
    Circulating Soluble Fas Concentration in Breast Cancer Patients
    Takayuki Ueno, Masakazu Toi and Takeshi Tominaga
    Clin Cancer Res November 1 1999 5 (11) 3529-3533;

  • Molecular Oncology, Markers, Clinical Correlates
    Evaluation of Soluble CD44v6 as a Potential Serum Marker for Head and Neck Squamous Cell Carcinoma
    Nicole L. W. Van Hal, Guus A. M. S. Van Dongen, Corlinda B. M. Ten Brink, Karl-Heinz Heider, Irene Rech-Weichselbraun, Gordon B. Snow and Ruud H. Brakenhoff
    Clin Cancer Res November 1 1999 5 (11) 3534-3541;

  • Molecular Oncology, Markers, Clinical Correlates
    Importance of Nuclear Morphology in Breast Cancer Prognosis
    William H. Wolberg, W. Nick Street and Olvi L. Mangasarian
    Clin Cancer Res November 1 1999 5 (11) 3542-3548;

  • Molecular Oncology, Markers, Clinical Correlates
    Genetically Fluorescent Melanoma Bone and Organ Metastasis Models
    Meng Yang, Ping Jiang, Zili An, Eugene Baranov, Lingna Li, Satoshi Hasegawa, Maraya Al-Tuwaijri, Takashi Chishima, Hiroshi Shimada, A. R. Moossa and Robert M. Hoffman
    Clin Cancer Res November 1 1999 5 (11) 3549-3559;

  • Molecular Oncology, Markers, Clinical Correlates
    Five Novel Immunogenic Antigens in Meningioma: Cloning, Expression Analysis, and Chromosomal Mapping
    Nicole Comtesse, Dirk Heckel, Alexander Rácz, Nicole Brass, Brenda Glass and Eckart Meese
    Clin Cancer Res November 1 1999 5 (11) 3560-3568;

  • Molecular Oncology, Markers, Clinical Correlates
    Deletion of Chromosome 1p and Loss of Expression of Alkaline Phosphatase Indicate Progression of Meningiomas
    Patrick Müller, Wolfram Henn, Isolde Niedermayer, Ralf Ketter, Wolfgang Feiden, Wolf-Ingo Steudel, Klaus D. Zang and Heike Steilen-Gimbel
    Clin Cancer Res November 1 1999 5 (11) 3569-3577;

  • Molecular Oncology, Markers, Clinical Correlates
    Androgen Receptor Gene Alterations and Chromosomal Gains and Losses in Prostate Carcinomas Appearing During Finasteride Treatment for Benign Prostatic Hyperplasia
    Pasi A. Koivisto, Johanna Schleutker, Heikki Helin, Conny Ehren-van Eekelen, Olli-Pekka Kallioniemi and Jan Trapman
    Clin Cancer Res November 1 1999 5 (11) 3578-3582;

Experimental Therapeutics, Preclinical Pharmacology

  • Experimental Therapeutics, Preclinical Pharmacology
    A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis
    Wen Y. Chen, Preveen Ramamoorthy, Nian-yi Chen, Robert Sticca and Thomas E. Wagner
    Clin Cancer Res November 1 1999 5 (11) 3583-3593;

  • Experimental Therapeutics, Preclinical Pharmacology
    Antitumor Activity of CEP-751 (KT-6587) on Human Neuroblastoma and Medulloblastoma Xenografts
    Audrey E. Evans, Kristin D. Kisselbach, Darrell J. Yamashiro, Naohiko Ikegaki, Anna Marie Camoratto, Craig A. Dionne and Garrett M. Brodeur
    Clin Cancer Res November 1 1999 5 (11) 3594-3602;

  • Experimental Therapeutics, Preclinical Pharmacology
    BAY 12-9566, A Novel Inhibitor of Matrix Metalloproteinases with Antiangiogenic Activity
    Carmen Gatto, Monica Rieppi, Patrizia Borsotti, Silvia Innocenti, Roberta Ceruti, Teresa Drudis, Eugenio Scanziani, Anna M. Casazza, Giulia Taraboletti and Raffaella Giavazzi
    Clin Cancer Res November 1 1999 5 (11) 3603-3607;

  • Experimental Therapeutics, Preclinical Pharmacology
    Radiotherapy and Dosimetry of 64Cu-TETA-Tyr3-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model
    Jason S. Lewis, Michael R. Lewis, P. Duffy Cutler, Ananth Srinivasan, Michelle A. Schmidt, Sally W. Schwarz, Margaret M. Morris, J. Philip Miller and Carolyn J. Anderson
    Clin Cancer Res November 1 1999 5 (11) 3608-3616;

  • Experimental Therapeutics, Preclinical Pharmacology
    Synergy of Topotecan in Combination with Vincristine for Treatment of Pediatric Solid Tumor Xenografts
    Joyce Thompson, E. Olusegun George, Catherine A. Poquette, Pamela J. Cheshire, Lois B. Richmond, Siebold S. N. de Graaf, Margaret Ma, Clinton F. Stewart and Peter J. Houghton
    Clin Cancer Res November 1 1999 5 (11) 3617-3631;

  • Experimental Therapeutics, Preclinical Pharmacology
    Enhanced Antitumor Activity of Paclitaxel in Combination with the Anticarcinoma Immunoconjugate BR96-Doxorubicin
    Pamela A. Trail, David Willner, Albert B. Bianchi, Arris J. Henderson, Mark D. TrailSmith, Emel Girit, Shirley Lasch, Ingegerd Hellström and Karl Erik Hellström
    Clin Cancer Res November 1 1999 5 (11) 3632-3638;

  • Experimental Therapeutics, Preclinical Pharmacology
    A Cell Type-specific and Gap Junction-independent Mechanism for the Herpes Simplex Virus-1 Thymidine Kinase Gene/Ganciclovir-mediated Bystander Effect
    Frédéric Princen, Pierre Robe, Chantal Lechanteur, Marc Mesnil, Jean-Michel Rigo, Jacques Gielen, Marie-Paule Merville and Vincent Bours
    Clin Cancer Res November 1 1999 5 (11) 3639-3644;

  • Experimental Therapeutics, Preclinical Pharmacology
    Direct Comparison of Liposomal Doxorubicin with or without Polyethylene Glycol Coating in C-26 Tumor-bearing Mice
    Ruey-Long Hong, Chang-Jen Huang, Yun-Long Tseng, Victor Fei Pang, Shui-Tsung Chen, Jun-Jen Liu and Fu-Hsiung Chang
    Clin Cancer Res November 1 1999 5 (11) 3645-3652;

  • Experimental Therapeutics, Preclinical Pharmacology
    The Outcome of Heregulin-induced Activation of Ovarian Cancer Cells Depends on the Relative Levels of HER-2 and HER-3 Expression
    Fengji Xu, Yinhua Yu, Xiao-Feng Le, Cinda Boyer, Gordon B. Mills and Robert C. Bast Jr.
    Clin Cancer Res November 1 1999 5 (11) 3653-3660;

  • Experimental Therapeutics, Preclinical Pharmacology
    Expression of Bisecting GlcNAc in Pediatric Brain Tumors and Its Association with Tumor Cell Response to Vinblastine
    Abdelhadi Rebbaa, Pauline M. Chou, Ivica Vucic, Bernard L. Mirkin, Tadanori Tomita and Eric G. Bremer
    Clin Cancer Res November 1 1999 5 (11) 3661-3668;

  • Experimental Therapeutics, Preclinical Pharmacology
    The Antiangiogenic Agent Linomide Inhibits the Growth Rate of von Hippel-Lindau Paraganglioma Xenografts to Mice
    David J. Gross, Israel Reibstein, Lola Weiss, Shimon Slavin, Ilan Stein, Michal Neeman, Rinat Abramovitch and Laura E. Benjamin
    Clin Cancer Res November 1 1999 5 (11) 3669-3675;

  • Experimental Therapeutics, Preclinical Pharmacology
    Eradication of Human Medulloblastoma Tumor Xenografts with a Combination of O6-Benzyl-2′-deoxyguanosine and 1,3-Bis(2-chloroethyl)-1-nitrosourea
    Demetrius M. Kokkinakis, Robert C. Moschel, Anthony E. Pegg and S. Clifford Schold
    Clin Cancer Res November 1 1999 5 (11) 3676-3681;

  • Experimental Therapeutics, Preclinical Pharmacology
    Pharmacokinetics of PK1 and Doxorubicin in Experimental Colon Tumor Models with Differing Responses to PK1
    Paul M. Loadman, Mike C. Bibby, John A. Double, Waleed M. Al-Shakhaa and Ruth Duncan
    Clin Cancer Res November 1 1999 5 (11) 3682-3688;

  • Experimental Therapeutics, Preclinical Pharmacology
    Simplified Production of a Recombinant Human Angiostatin Derivative That Suppresses Intracerebral Glial Tumor Growth
    Patricio I. Meneses, Lauren E. Abrey, Katherine A. Hajjar, S. Humayun Gultekin, Robert M. Duvoisin, Kenneth I. Berns and Myrna R. Rosenfeld
    Clin Cancer Res November 1 1999 5 (11) 3689-3694;

Cancer Biology, Immunology, Cytokines

  • Cancer Biology, Immunology, Cytokines
    Antagonistic Effect of NK4, a Novel Hepatocyte Growth Factor Variant, on in Vitro Angiogenesis of Human Vascular Endothelial Cells
    Wen G. Jiang, Steve E. Hiscox, Christian Parr, Tracey A. Martin, Kunio Matsumoto, Toshikazu Nakamura and Robert E. Mansel
    Clin Cancer Res November 1 1999 5 (11) 3695-3703;

  • Cancer Biology, Immunology, Cytokines
    Lysophosphatidic Acid Induces Urokinase Secretion by Ovarian Cancer Cells
    Terri B. Pustilnik, Veronica Estrella, Jon R. Wiener, Muling Mao, Astrid Eder, Mary-Anne V. Watt, Robert C. Bast Jr. and Gordon B. Mills
    Clin Cancer Res November 1 1999 5 (11) 3704-3710;

  • Cancer Biology, Immunology, Cytokines
    Constitutive and Inducible Interleukin 8 Expression by Hypoxia and Acidosis Renders Human Pancreatic Cancer Cells More Tumorigenic and Metastatic
    Qian Shi, James L. Abbruzzese, Suyun Huang, Isaiah J. Fidler, Qinghua Xiong and Keping Xie
    Clin Cancer Res November 1 1999 5 (11) 3711-3721;

Letters to the Editor

  • Letters to the Editor
    Correspondence re: S. Shimoyama et al., Increased Serum Angiogenin Concentration in Colorectal Cancer Is Correlated with Cancer Progression. Clin. Cancer Res., 5: 1125–1130, 1999.
    Sagrario Montero, Belén Lloveras, Hernán Cortés-Funes and Ramon Colomer
    Clin Cancer Res November 1 1999 5 (11) 3722-3723;

  • Letters to the Editor
    Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. Clin. Cancer Res., 4:287–294, 1998.
    Paula Soares and Manuel Sobrinho-Simões
    Clin Cancer Res November 1 1999 5 (11) 3724-3725;

Back to top
PreviousNext
November 1999
Volume 5, Issue 11
  • Table of Contents

Sign up for alerts

Jump to

  • Editorials
  • Advances in Brief
  • Clinical Trials
  • Molecular Oncology, Markers, Clinical Correlates
  • Experimental Therapeutics, Preclinical Pharmacology
  • Cancer Biology, Immunology, Cytokines
  • Letters to the Editor
Advertisement
  • Most Cited
  • Most Read
Loading
  • Targeted TNF Potentiates the Efficacy of a Peptide Vaccine
  • WNT/β-catenin–Associated Immune Exclusion across Cancers
  • Alisertib for Neuroendocrine Prostate Cancer
  • Genotyping of HCC in the Clinic
  • Single-Cell RNA Sequencing of Pancreatic Cancer
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement